🇺🇸 BREXUCABTAGENE AUTOLEUCEL in United States

599 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cytokine Release Syndrome — 176 reports (29.38%)
  2. Immune Effector Cell-Associated Neurotoxicity Syndrome — 105 reports (17.53%)
  3. Squamous Cell Carcinoma Of Skin — 53 reports (8.85%)
  4. Myelodysplastic Syndrome — 44 reports (7.35%)
  5. Hypotension — 42 reports (7.01%)
  6. Pyrexia — 40 reports (6.68%)
  7. Disease Progression — 38 reports (6.34%)
  8. Febrile Neutropenia — 36 reports (6.01%)
  9. Basal Cell Carcinoma — 33 reports (5.51%)
  10. Death — 32 reports (5.34%)

Source database →

BREXUCABTAGENE AUTOLEUCEL in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is BREXUCABTAGENE AUTOLEUCEL approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BREXUCABTAGENE AUTOLEUCEL in United States?

Marketing authorisation holder not available in our data.